Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Still Very Positive

<< Previous

Bullboard Posts

Next >>

Post by pattyb77on Feb 09, 2021 5:03pm

325 Views

Post# 32518041

Still Very Positive

Nice pullback today. weak hands got out and little selling pressure by EOD. the bid/ask Spread is showing $0.09 on the ask... so this thing can easily be back up to 0.09 tomorrow morning with a small amount of people slapping the ask. Keep your heads up!

Also: can we stop with the bashing and other non sense... lets keep it about KLY in here

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing